ArticleJournal of clinical gastroenterology
Real-world Study of Three-gas Breath Testing Nationwide and the Association With Symptoms.
Article in Journal of clinical gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Do Multi-Omics Approaches Improve the Diagnosis of Microbial Overgrowth Syndromes?Current gastroenterology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
GOALS AND
backgroundHydrogen (H 2 ) breath testing (BT) is used to diagnose small intestinal bacterial overgrowth (SIBO), and methane (CH 4 ) to diagnose constipation. Recently, a third microbially derived gas, hydrogen sulfide (H 2 S), was added to BT and associated with diarrhea. Here, we assess a 3-gas BT nationwide, comparing the results to gastrointestinal (GI) symptoms. STUDY: Consecutive subjects (N=6000) undergoing 3-gas at-home BT were asked to complete a symptom questionnaire. Substrate choice (glucose or lactulose) was at physician's discretion. H 2 , CH 4, and H 2 S levels, and presence/absence of SIBO (≥20 ppm rise in H 2 within 90 min), intestinal methanogen overgrowth (IMO) (≥10 ppm CH 4 ), and intestinal sulfide overproduction (ISO, defined here as ≥2 ppm H 2 S) were compared with symptom severity. Gas interactions and symptoms' correlations were determined using machine learning (Uniform Manifold Approximation and Projection [UMAP]).
resultsA total of 3004 subjects who completed breath tests and primary questions were included. Bloating was the most common reason for BT. More subjects reported severe or very severe symptoms for bloating (52.9%) than diarrhea (17.8%), constipation (17.1%), or abdominal pain (17.1%). SIBO positivity was more common using lactulose (27%) versus glucose (7.3%). Higher H 2 levels correlated with more severe diarrhea ( P =0.031), and CH 4 levels correlated with constipation ( P =0.002). Higher H 2 S levels correlated with more severe diarrhea ( P <0.0001), urgency ( P =0.003), and abdominal pain ( P =0.01). UMAP revealed that H 2 S levels increased symptom severity, and ISO (alone or with SIBO/IMO) drove greater diarrhea, urgency, bloating, and overall severity, with highest pain and severity in ISO alone.
conclusionsH 2 , CH 4 , and H 2 S are associated with unique symptoms: CH 4 with constipation and H 2 S with diarrhea and a greater overall symptom severity. Glucose appears less sensitive than lactulose, suggesting it could potentially miss some symptomatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.